Background: The use of synthetic analogues of somatostatin following pancreatic surgery is contro-
Introduction
Pancreatic resection is performed to treat pancreatic diseases including malignancy and chronic pancreatitis. In most series, the incidence of complications following pancreatic surgery varies from 30% to 60% and the mortality rate is <5%. [1] [2] [3] The major complication following pancreatic resection is postoperative pancreatic leak or fistula. Recent reviews have described the incidence of pancreatic leak or fistula as 37%. 4 Various methods have been suggested to decrease the incidence of pancreatic complications, but the most common approach has involved the use of somatostatin or its synthetic analogues. Somatostatin and its analogues decrease the exocrine and endocrine pancreatic secretions by binding to the somatostatin receptors on the exocrine and endocrine cells, and decrease the secretions of these cells possibly by acting as dephosphorylators and by altering the calcium transport across the cell membranes. 5 Decreasing the volume of pancreatic secretion may decrease the incidence of pancreatic leak or fistula. 6 However, the use of somatostatin and its analogues is controversial and whereas some randomized controlled trials (RCTs) and systematic reviews recommend 7, 8 prophylactic somatostatin analogues (SAs) in pancreatic resections, others do not. 9, 10 These treatments may potentially decrease morbidity and mortality following pancreatic surgery, but it is possible that they may have no therapeutic benefit and may be associated with negative outcomes. A systematic review was carried out to determine whether prophylactic SAs should be used routinely in pancreatic surgery.
Materials and methods

Identification of trials and data extraction
Only RCTs of parallel design, irrespective of blinding, sample size, publication status (i.e. whether published as full text or presented only as an abstract at a conference) and language, were included. Quasi-randomized trials and other study designs were excluded. Only trials involving patients undergoing a pancreatic surgical procedure (pancreatic resection, pancreatic duct drainage procedures or cyst drainage procedures) for any pancreatic disease were considered. Only trials involving the administration of perioperative somatostatin (or an analogue of this hormone, such as octreotide) against a comparator of placebo or no intervention were considered. The Cochrane Upper Gastrointestinal and Pancreatic Diseases Group Controlled Trials Register, 11 the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library, MEDLINE, EMBASE and Science Citation Index Expanded 12 were searched for trials published up to November 2009. The references of the identified trials were also searched to identify further relevant trials.
Two reviewers (RSK and KSG) independently identified the trials for inclusion. In addition, the population characteristics (such as sex, age, proportion of pancreaticoduodenectomies, disease aetiology) and the interventions used in each trial were extracted. The methodological qualities of the trials were assessed independently, without masking the trial names. Any unclear or missing information was obtained by contacting the authors of the individual trials. If there was any doubt as to whether trials had shared the same patients -completely or partially (by identifying common authors and centres) -the authors of the trials were contacted to establish whether the trial report had been duplicated. Any differences in opinion were resolved through discussion.
Outcomes
Data for the following outcomes were extracted: postoperative mortality; re-operation; postoperative complications (anastomotic leak, pancreatic fistula, pancreatitis, sepsis, renal failure, bleeding, abdominal collections, infected abdominal collections, delayed gastric emptying, pulmonary complications, shock, number of complications, number of patients with any complications); drug-related complications (treatment withdrawal, number with adverse effects resulting from treatment), and hospital stay (total hospital stay, intensive care unit [ICU] stay). Pancreatic fistula has been graded as A, B and C by consensus amongst surgeons. 13 Any pancreatic fistula, however defined, was included by the authors as one of the outcomes. Clinically significant pancreatic fistula was included as another outcome, for which only trials which featured data on grades B and C as distinct from grade A (not clinically significant) were included.
Subgroup analyses of trials with low risk of bias vs. those with high risk of bias, different interventions (somatostatin and octreotide), different aetiologies (malignancy and chronic pancreatitis), different procedures (pancreatoduodenectomy, distal pancreatectomy and pancreatic drainage procedures) and different methods of management of the pancreatic stump (pancreatogastrostomy and pancreatojejunostomy) were planned.
Assessment of risk of bias
Risk of bias can result in the incorrect estimation of the effectiveness of an intervention. [14] [15] [16] [17] The risk of bias in the trials was assessed in different domains, including sequence generation, allocation concealment, blinding (of participants, personnel and outcome assessors), incomplete outcome data, selective outcome reporting and other sources of bias, such as baseline imbalance, early stopping bias, academic bias and sources of funding bias. 18, 19 Trials which were classified as being at low risk of bias in sequence generation, allocation concealment, blinding, incomplete data and selective outcome reporting were considered as low bias-risk trials.
Statistical methods
Meta-analyses were performed according to the recommendations of the Cochrane Collaboration 18 using the software package Revman 5.0 (Nordic Cochrane Centre, Cochrane Collaboration, Copenhagen, Denmark). For dichotomous outcomes, the risk ratio (RR) was calculated with a 95% confidence interval (CI). For continuous outcomes, the mean difference (MD) or standardized mean difference (SMD) was calculated with its 95% CI. A random-effects model 20 and a fixed-effect model 21 were used. In cases of discrepancy between the two models, both the results were reported; otherwise only the results from the fixed-effect model were reported. The analysis was performed on an 'intention-to-treat' basis 22 whenever possible, but, in order to allow for dropouts and withdrawals between randomization and intervention or control, the 'available case analysis' 18 was adopted. The degree of heterogeneity was measured by chisquared test with significance set at a P-value of 0.10, and the quantity of heterogeneity was measured by I 2 . 23 An I 2 value >30% was considered to represent statistically significant heterogeneity. Standard deviation was imputed from standard error or from P-values if it was not given directly in the trial reports, according to Cochrane Collaboration guidelines. 18 The chi-squared test for subgroup differences set at a P-value of 0.05 was performed to identify any subgroup differences.
A funnel plot was used to explore bias. 24, 25 Asymmetry in the funnel plot of trial size against treatment effect was used to assess the risk of bias. The linear regression approach was performed to determine the funnel plot asymmetry. 24 
Results
Description of studies A total of 742 references were identified through electronic searches of the Cochrane Upper Gastrointestinal and Pancreatic Diseases Group Controlled Trials Register 11 and the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library (n = 74), MEDLINE (n = 390), EMBASE (n = 176), Science Citation Index Expanded (n = 102). A total of 192 duplicates and 505 clearly irrelevant references identified by reading the abstracts were excluded (Fig. 1) . Forty-five references were retrieved for further assessment. No references were identified through scanning the reference lists of the RCTs identified. Of the 45 references, 16 were excluded because they referred to quasi-randomized studies, prospective nonrandomized studies or comments that did not contain data from an RCT. Of the remaining 29 references, 12 were multiple reports, which resulted in the identification of a total of 17 RCT reports which fulfilled the inclusion criteria. All 17 trials were completed trials and were able to provide data for the analyses. Important details of the included trials are shown in Table 1 . Only two trials were considered to be at low risk of bias. 26, 27 Participants The 17 trials included 2143 patients (Table 1 ). A total of 237 patients were involved in six trials comparing somatostatin vs. control [27] [28] [29] [30] [31] [32] and 1564 patients were involved in 10 trials comparing octreotide vs. control. 7, 8, 10, 27, [33] [34] [35] [36] [37] [38] The remaining patients were involved in one trial comparing vapreotide vs. control. 9 Overall, 1457 patients underwent pancreatoduodenectomy, 1143 patients had malignancy and 587 had chronic pancreatitis in the trials that reported these characteristics. The mean age of the individuals in the trials varied between 43 years and 65 years. The mean proportion of females varied between 15% and 48%. There was no difference in the characteristics of patients in the intervention and control groups in any of the trials that reported these baseline characteristics. 
References excluded
Quasi-randomized Non-randomized Comments/reviews Out of scope Awaiting assessment
RCTs withdrawn by outcome n = 0
Multiple reports n = 12
References retrieved for more detailed evaluation n = 45
Potentially appropriate RCT to be included n = 29
References included in meta-analysis n = 29
RCTs included in meta-analysis n = 17 Figure 1 Flow chart showing the search strategy used to identify trials. RCT, randomized controlled trial 
Subgroup analysis
The following planned subgroup analyses were performed: different interventions (somatostatin and octreotide); different aetiologies (malignancy and chronic pancreatitis), and different procedures (pancreatoduodenectomy). A planned subgroup analysis of other procedures (distal pancreatectomy and pancreatic drainage procedures), and the different methods of management of pancreatic stump (pancreatogastrostomy and pancreatojejunostomy) could not be performed as the outcome data for the different subgroups were not available from the trials. Subgroup analysis based on the risk of bias in the trials could not be performed as only two trials were at low risk of bias. 26, 27 There was no difference in any of the primary outcomes between intervention and control groups in the different subgroups.
The secondary outcomes for which there were statistically significant differences between the two groups are described below.
Stratified by intervention Somatostatin vs. no intervention
The decrease in incidences of pancreatic fistula (RR 0.35, 95% CI 0.14-0.88), reduced number of patients with any complications (RR 0.50, 95% CI 0.27-0.93) and reduction in duration of hospital stay (MD -6.79 days, 95% CI -10.65 to -2.94; mean hospital stay 22.1 days in the somatostatin group vs. 27.6 days in controls) in the somatostatin group compared with the control group were statistically significant. There was no difference between the two groups in any of the other outcomes. Octreotide vs. no intervention The lower incidences of pancreatic fistula (RR 0.61, 95% CI 0.49-0.77) and abdominal collections (RR 0.61, 95% CI 0.42-0.89), lower number of complications (rate ratio 0.66, 95% CI 0.55-0.80) and lower number of patients with any complications (RR 0.68, 95% CI 0.58-0.80) in the octreotide group compared with the control group were statistically significant. There was no difference in any of the other outcomes between the two groups.
The only outcome in which the test for subgroup differences was positive was that of hospital stay (P = 0.001).
Stratified by aetiologies Malignancy Decreases in the incidence of pancreatic fistula (RR 0.52, 95% CI 0.35-0.77) and sepsis (RR 0.28, 95% CI 0.08-0.97), number of complications (rate ratio 0.61, 95% CI 0.48-0.77) and number of patients with complications (RR 0.60, 95% CI 0.45-0.79) in the SA group over the control group were statistically significant. The decrease in the duration of hospital stay in the SA group over that in the control group (MD -7.57 days, 95% CI -11.29 to -3.84; mean hospital stay 25.0 days in the SA group vs. 32.1 days in controls) was statistically significant (Fig. 5) . There was no difference in any of the other outcomes between the two groups.
Chronic pancreatitis Reductions in the incidence of pancreatic fistula (RR 0.40, 95% CI 0.24-0.64) and number of patients with any complications (RR 0.54, 95% CI 0.38-0.77) in the intervention group compared with the control group were statistically significant. There was no difference in any of the other outcomes between the two groups.
The only outcome in which the test for subgroup differences was positive was hospital stay (P = 0.03).
Stratified by procedure
A planned subgroup analysis of distal pancreatectomy and pancreatic drainage procedures could not be performed as the data for these procedures were not available from the trials. Only the subgroup of patients undergoing pancreatoduodenectomy was reported.
Pancreatoduodenectomy There was no statistically significant difference between the SA and control group for any of the outcomes.
Variations in statistical analysis
Adopting the random-effects model or calculating the risk difference did not change the results. Sensitivity analysis using empirical continuity correction factors 39 was not performed because 
Total (95% CI)
Total events Heterogeneity: x² = 6.89, d.f. = 4 (P = 0.14); I² = 42% Test for overall effect: Z = 0.37 (P = 0.71) 
Reporting bias
The funnel plot of the primary outcomes did not show any reporting bias (Fig. 6 ). Egger's linear regression approach to identifying publication bias 24 did not reveal any bias for the outcome perioperative mortality (P = 0.3199). This was not calculated for the outcome re-operation because few trials included that outcome.
Discussion
Somatostatin analogues did not decrease rates of perioperative mortality and re-operation in patients undergoing pancreatic surgery. The main indication for re-operation is the presence of a pancreatic fistula-associated sepsis or organ dysfunction. 13 There is no universal definition of pancreatic fistula or pancreatic leak and incidences vary depending on the definitions used. An international study group of surgeons 13 have graded postoperative pancreatic fistulas by consensus as A, B and C. Grade A fistulas are transient and do not have any clinical impact. Grade B fistulas require alteration in the management of the patient. Grade C fistulas require major alterations in the management of the patient and usually indicate re-operation. Grade B and C fistulas have significant clinical impact and may contribute to increased morbidity and mortality. In this review, only trials in which data on grade B or C fistulas were available separately from grade A were included for the outcome of clinically significant pancreatic fistula (grades B and C). The overall incidence of pancreatic fistula was lower in the SA group. Only three trials distinguished between any pancreatic fistula and clinically significant pancreatic fistula. 26, 27, 33 There was no difference between the SA and control groups in the incidence of clinically significant pancreatic fistula. It is likely that some of the pancreatic fistulas that were reported in the other trials were clinically significant. However, in the absence of data on the proportion of these fistulas that were clinically significant, such trials could not be included for the outcome 'clinically significant pancreatic fistulas' and could be included Figure 5 Comparison of somatostatin analogues vs. no intervention. Subgroup analysis stratified by different aetiologies: effects on hospital stay. SD, standard deviation; 95% CI, 95% confidence interval only for the outcome 'all pancreatic fistulas' . That only a few trials were included under the outcome 'clinically significant pancreatic fistulas' may explain the lack of any statistically significant difference between the SA and control groups. Alternatively, the lack of a statistically significant difference may reflect the lack of effect. In patients undergoing pancreatic surgery for malignancy, a decrease in hospital stay was noted in the SA group. This suggests that SAs decreased clinically significant fistulas in patients undergoing pancreatic surgery for cancer. Overall postoperative complications were lower in the intervention group than the control group. However, there was no difference between the two groups in length of hospital stay in the main analysis. The possible reasons for the absence of difference in total hospital stay include a lack of effect of SAs with regard to incidence of re-operation, anastomotic leak or clinically significant pancreatic fistulas and the fact that pancreatic fistulas are often managed at the patient's home (as community-based treatment).
Pancreatic fistulas that are amenable to community-based treatment may decrease the quality of life of the patients concerned during the time they take to close, increase the length of the convalescence period, thus causing a later return to work and resulting in major cost implications for patients, patients' carers and patients' employers, and increase the costs associated with the provision of community-based treatment, despite the fact that SAs do not appear to reduce hospital stay.
As far as the interventions were concerned, somatostatin must be administered by continuous i.v. infusion for approximately 1 week. This can decrease the patient's mobility. By contrast, octreotide is administered subcutaneously thrice per day, allowing good patient mobility. Its other advantage is that it can be administered even in patients with difficult venous access, thereby increasing compliance. The adverse effects associated with the intervention were mainly minor, such as pain at the injection site. No serious adverse effects were reported in any of the trials. Of the trials that reported the withdrawal of intervention, the treatment was stopped in about 1.5% of the 540 patients. In high-income countries, the cost of an entire course of octreotide is less than the cost of 1 day in hospital. There was no difference in length of hospital stay between the two groups in the main analysis. However, the subgroup analysis revealed a shorter hospital stay in the intervention group in the somatostatin (P = 0.0006) and malignancy (P < 0.0001) subgroups. Only three trials were included in each of these subgroups, 27, 28, 34 one of which featured in both subgroups. 27 It is not clear whether the lower hospital stay in the intervention group in these subgroups is because of the intervention effect or because of the numerous subgroup analyses that were performed. The lack of information on pancreatic fistula (i.e. whether it was clinically significant or not) does not help us to reach a conclusion. Patients with chronic pancreatitis have a lower risk of postoperative complications than those with malignancy and this may be because the tissue fibrosis usually seen in patients with chronic pancreatitis facilitates the anastomotic procedure. 34 This logical reasoning combined with the very low P-value obtained suggests that the decrease in hospital stay in patients undergoing pancreatic surgery for malignancy reflects the true effect of SAs. Further evaluation of the cost-effectiveness of SAs in pancreatic surgery is necessary.
Somatostatin analogues reduce perioperative complications but do not reduce perioperative mortality. In patients undergoing pancreatic surgery for malignancy, they shorten hospital stay. (B) Figure 6 Funnel plots of comparison of somatostatin analogues vs. no intervention for outcomes (A) perioperative mortality and (B) re-operation. SE, standard error; RR, risk ratio differently, depending on the reader's perspectives and circumstances. Please consider the conclusions presented carefully. They are the opinions of the review authors and are not necessarily shared by the Cochrane Collaboration.
